Evidence map›Paper›PMID 41827884›Full record

ReviewCells2026

Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes.

Feifei Su, Woojin S Kim, Glenda M Halliday, YuHong Fu

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Feifei SuBrain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0009-0007-0680-5159
Woojin S KimBrain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0002-4707-933X
Glenda M HallidayBrain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0003-0422-8398
YuHong FuBrain and Mind Centre & Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0003-4539-2039

Funding

Infectious Disease Society of America ALZ-ID-0000000016NHMRC Senior Investigator grant #1176607
6 · The paper itself

Abstract

Alpha-synuclein (αSyn) is one of the most abundant proteins in the nervous system and is currently associated with devastating synucleinopathies, yet its biology extends far beyond this. In this review, we suggest that αSyn-driven disease emerges within specific neural circuits through the combined effects of cell-type-specific roles, subcellular environments, post-translational modifications (PTMs), and co-pathology. These interacting and additive dimensions, rather than αSyn alone, generate the pathological diversity, shaping whether pathology manifests as Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or mixed dementia phenotypes. We integrate recent advances on the physiological roles of αSyn in neurons and glia (astrocytes, oligodendrocytes, and microglia), its compartment-dependent (e.g., synaptic and nuclear) functions, and the molecular transitions (e.g., mediated by pS129) that convert functional assemblies into pathogenic conformers. Building on this foundation, we outline mechanisms through which these factors contribute to disease-specific vulnerability, progression, and clinical heterogeneity. Finally, we highlight how this multidimensional perspective on αSyn biology can inform the development of next-generation biomarkers that support precision therapies across distinct disorders.

Indexed as

alpha-SynucleinNerve DegenerationNeurodegenerative DiseasesAnimalsHumansLewy Body DiseaseMultiple System AtrophyNeurogliaNeuronsParkinson DiseasePhenotypeProtein Processing, Post-Translationalalpha-Synucleinalpha-synucleindementia with Lewy bodiesgliamultiple system atrophyneuronParkinson’s diseaseParkinson’s disease dementiapathology modelingpost-translational modificationseed amplification assay

Identifiers

PMID41827884
PMCPMC12985178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.